Comparing Stevanato Group (STVN) & Its Rivals
by Amy Steele · The Cerbat GemStevanato Group (NYSE:STVN – Get Free Report) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it compare to its peers? We will compare Stevanato Group to similar businesses based on the strength of its risk, institutional ownership, profitability, dividends, earnings, analyst recommendations and valuation.
Profitability
This table compares Stevanato Group and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Stevanato Group | 10.99% | 10.43% | 6.16% |
| Stevanato Group Competitors | -540.59% | -166.46% | -13.58% |
Earnings & Valuation
This table compares Stevanato Group and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Stevanato Group | $1.34 billion | $158.21 million | 22.49 |
| Stevanato Group Competitors | $2.26 billion | $55.88 billion | -13.91 |
Stevanato Group’s peers have higher revenue and earnings than Stevanato Group. Stevanato Group is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
54.4% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 15.2% of shares of all “Life Sciences Tools & Services” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and recommmendations for Stevanato Group and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Stevanato Group | 0 | 5 | 2 | 2 | 2.67 |
| Stevanato Group Competitors | 947 | 3162 | 5476 | 177 | 2.50 |
As a group, “Life Sciences Tools & Services” companies have a potential downside of 4.10%. Given Stevanato Group’s peers higher probable upside, analysts clearly believe Stevanato Group has less favorable growth aspects than its peers.
Volatility & Risk
Stevanato Group has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Stevanato Group’s peers have a beta of 0.94, indicating that their average stock price is 6% less volatile than the S&P 500.
Summary
Stevanato Group peers beat Stevanato Group on 7 of the 13 factors compared.
Stevanato Group Company Profile
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.